Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Is The Projected Valuation Of The Lupus Nephritis Market In The Coming Years?

In the past few years, the lupus nephritis market has seen robust growth. It’s projected to expand from $1.94 billion in 2024 to $2.08 billion in 2025, experiencing a 7.4% compound annual growth rate (CAGR). The increase during the historic period can be ascribed to factors such as heightened investment in lupus nephritis research, a surge in autoimmune diseases, rising healthcare costs, increased acceptance of biologics, and the growing trend towards telemedicine.

The market size for lupus nephritis is projected to witness a robust expansion in the coming years. By 2029, it is forecasted to hit $2.78 billion with a Compound Annual Growth Rate (CAGR) of 7.5%. The expected growth during this period can be linked to factors such as increasing physician knowledge, greater utilization of biologic treatments, a rise in specialized clinics, a growing focus on renal transplantation, and enhanced access to nephrological services. In the prediction period, significant trends include progression in biologic treatments, personalized medicinal strategies, emerging diagnostic markers, expansion in clinical trials, and advancements in the field of stem cell therapy.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22044&type=smp

Which Growth Drivers Are Shaping The Lupus Nephritis Market Outlook?

The upsurge in genetic predisposition occurrences is projected to stimulate the expansion of the lupus nephritis market in the future. Genetic predisposition involves the inherited genetic tendencies of an individual that amplify their probability of acquiring certain diseases or conditions. The rise in genetic predisposition can be attributed to factors such as heredity, environmental impacts, and mutations in certain genes. The escalating instances of genetic predispositions considerably influence the progression of lupus nephritis, underscoring the significance of inherited genetic elements in autoimmune disorders, particularly those that affect the kidney’s functionality. For example, the UK CF Registry, managed by the UK-based philanthropic organization Cystic Fibrosis Trust, reported in October 2024 that the number of registered patients increased from 11,148 in 2022 to 11,318 in 2024, signifying a 1.52% surge in individuals diagnosed with cystic fibrosis (CF). Consequently, the rising instances of genetic predispositions are fueling the expansion of the lupus nephritis market.

What Is The Segment Breakdown Of The Lupus Nephritis Market?

The lupus nephritismarket covered in this report is segmented –

1) By Stage: Class 1; Class 2; Class 3; Other Stages

2) By Drug Class: Immunosuppressive Drugs; Corticosteroids; Biological Agents; Antimalarial Drugs

3) Route Of Administration: Oral; Parenteral; Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy

5) By End-User: Hospitals; Specialty Clinics; Other End-Users

Subsegments:

1) By Class 1: Asymptomatic Cases; Mild Proteinuria; Incidental Diagnosis.

2) By Class 2: Mild Hematuria; Low-Grade Proteinuria; Minimal Immune Complex Deposition.

3) By Class 3: Active Lesions; Chronic Sclerotic Lesions; Crescent Formation.

4) By Other Stages: Class 4 (Diffuse Lupus Nephritis); Class 5 (Membranous Lupus Nephritis); Class 6 (Advanced Sclerotic Lupus Nephritis)

What New Opportunities Are Emerging From Trends In The Lupus Nephritis Market?

In the lupus nephritis market, key companies are focused on developing advanced second-generation calcineurin inhibitors to boost treatment effectiveness and improve long-term kidney outcomes. These inhibitors help reduce inflammation and prevent kidney damage by modulating the immune system. For example, in September 2024, Aurinia Pharmaceuticals Inc., a Canadian biopharmaceutical company, announced that Japan’s Ministry of Health, Labour, and Welfare approved LUPKYNIS (voclosporin) for lupus nephritis treatment. The drug is used alongside mycophenolate mofetil (MMF), supported by data from the AURORA Clinical Program demonstrating its safety and efficacy. This approval marks an important milestone in expanding treatment options for lupus nephritis patients in Japan, enhancing disease management.

Who Are The Major Stakeholders Operating In The Lupus Nephritis Market?

Major companies operating in the lupus nephritis market are F. Hoffmann-La Roche Ltd., Bristol Myers Squibb, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Genentech, Astrazeneca PLC, Biocon Biologics, Hanmi Pharmaceutical Co. Ltd., Sana Biotechnology Inc., RemeGen Co. Ltd., Aurinia Pharmaceuticals Inc., Otsuka Pharmaceutical Co. Ltd., Equillium Inc., Anthera Pharmaceuticals Inc., Atara Biotherapeutics Inc., Artiva Biotherapeutics, Caribou Biosciences, Nkarta Inc., Adicet Bio Inc., Lupus Research Alliance, Kyverna Therapeutics Inc., Kezar Life Sciences, Bionxt Solutions.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/lupus-nephritis-global-market-report

Which Region Is Likely To Register The Fastest Growth In The Lupus Nephritis Market?

Asia-Pacific was the largest region in the lupus nephritis market in 2024. The regions covered in the lupus nephritis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=22044&type=smp

Browse Through More Reports Similar to the Global Lupus Nephritis Market 2025, By The Business Research Company

Systemic Lupus Erythematosus Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/systemic-lupus-erythematosus-treatment-global-market-report

Diabetic Kidney Disease Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/diabetic-kidney-disease-global-market-report

Kidney Transplant Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/kidney-transplant-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model